tanshinone VI: isolated from the root of Salvia miltiorrhiza; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Salvia | genus | A genus in the mint family (LAMIACEAE).[MeSH] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 149138 |
| CHEMBL ID | 390741 |
| SCHEMBL ID | 14417698 |
| MeSH ID | M0240363 |
| Synonym |
|---|
| sodium tanshinone vi 1-phenolate |
| CHEMBL390741 |
| danshenxinkun a |
| 1-hydroxy-2-(1-hydroxypropan-2-yl)-8-methylphenanthrene-3,4-dione |
| tanshinone vi |
| 3,4-phenanthrenedione, 1-hydroxy-2-(2-hydroxy-1-methylethyl)-8-methyl- |
| 121064-74-2 |
| i91bp9h8pf , |
| 65907-75-7 |
| unii-i91bp9h8pf |
| 1,4-phenanthrenedione, 3-hydroxy-2-(2-hydroxy-1-methylethyl)-8-methyl- |
| SCHEMBL14417698 |
| AC-34178 |
| bdbm50476406 |
| DTXSID20923661 |
| AKOS032949036 |
| 3-hydroxy-2-(1-hydroxypropan-2-yl)-8-methylphenanthrene-1,4-dione |
| MS-24242 |
| 231292-03-8 |
| XD176696 |
| CS-0024046 |
| HY-N3680 |
| AKOS040760361 |
| 1-hydroxy-2-(1-hydroxypropan-2-yl)-8-methyl-3,4-dihydrophenanthrene-3,4-dione |
Tanshinone VI is an abietane diterpene extracted from the root of Salvia miltiorrhiza Bunge. It is a Chinese traditional crude drug, "Tan-Shen"
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tanshinone VI is an abietane diterpene extracted from the root of Salvia miltiorrhiza Bunge (Labiatae), a Chinese traditional crude drug, "Tan-Shen"." | ( Inhibition of bone resorption by Tanshinone VI isolated from Salvia miltiorrhiza Bunge. Dal Piaz, F; De Tommasi, N; Narducci, P; Nicolin, V; Nori, SL, 2010) | 1.36 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The lack of toxic effects at the dosage used makes Tanshinone VI a good candidate for its therapeutic use in humans." | ( Tanshinone VI inhibits the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Bossi, F; Nicolin, V; Nori, SL; Valentini, R; Viggiano, A, ) | 1.82 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0007 | 2.4652 | 9.2100 | AID291914; AID291915 |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0030 | 2.6002 | 8.5100 | AID291914; AID291915 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID291916 | Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay | 2007 | Journal of natural products, Jul, Volume: 70, Issue:7 | Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. |
| AID291918 | Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay | 2007 | Journal of natural products, Jul, Volume: 70, Issue:7 | Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. |
| AID291915 | Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay | 2007 | Journal of natural products, Jul, Volume: 70, Issue:7 | Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. |
| AID291914 | Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay | 2007 | Journal of natural products, Jul, Volume: 70, Issue:7 | Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||